Midostaurin, a type-I inhibitor targeting the active kinase conformation, combined with 7 + 3 chemotherapy improved overall survival (OS; median 74.7 vs 25.6 months) in newly diagnosed FLT3-mutant AML, establishing a frontline standard for fit patients (Bazzell et al., 2022; Burchert et al., 2020). Here, FLT3 is linked to acute myeloid leukemia.